Drug Landscape ›
Carvedilol 25mg ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 63
Most-reported reactions
Death — 11 reports (17.46%) Dyspnoea — 8 reports (12.7%) Fatigue — 8 reports (12.7%) Dizziness — 7 reports (11.11%) Diarrhoea — 6 reports (9.52%) Hypotension — 6 reports (9.52%) Bradycardia — 5 reports (7.94%) Acute Kidney Injury — 4 reports (6.35%) Asthenia — 4 reports (6.35%) Syncope — 4 reports (6.35%)
Source database →
Carvedilol 25mg in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Carvedilol 25mg approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Carvedilol 25mg in United States?
Ahn-Gook Pharmaceuticals Co.,Ltd is the originator. The local marketing authorisation holder may differ — check the official source linked above.